Photo from wikipedia
Controversies on sub‐populations most sensitive to therapy and the best timing of starting the treatment still surround the use of immunomodulatory drugs in COVID‐19. Click to show full abstract
Controversies on sub‐populations most sensitive to therapy and the best timing of starting the treatment still surround the use of immunomodulatory drugs in COVID‐19.
Keywords:
open randomised;
early administration;
covid pneumonitis;
pneumonitis open;
tofacitinib covid;
administration tofacitinib
Journal Title: European Journal of Clinical Investigation
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Clinical Investigation
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!